ReviewFrontiers in physiology2025
Mitochondria as the central regulator of cell death in bronchopulmonary dysplasia.
Review in Frontiers in physiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- SIRT3 deficiency drives alveolar epithelial mitochondrial dysfunction in bronchopulmonary dysplasia via PDHA1 hyperacetylation.iScience · 2026Article
- When stress exceeds developmental capacity: rethinking cell death in bronchopulmonary dysplasia.Frontiers in pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bronchopulmonary dysplasia (BPD) remains a major chronic respiratory condition affecting preterm infants, characterized by impaired alveolar and vascular development. While the roles of oxidative stress and inflammation are recognized, this review provides a novel synthesis by positioning mitochondrial dysfunction as the central hub integrating these injurious processes with the activation of diverse cell death pathways in BPD pathogenesis. We critically explore how mitochondrial damage, driven by hyperoxia and inflammation, not only amplifies cellular injury but also orchestrates specific modes of programmed cell death, particularly apoptosis, pyroptosis, necroptosis, autophagy, ferroptosis, and the newly delineated cuproptosis. A key contribution is elucidating the crosstalk between these pathways and their collective impact on alveolar simplification and vascular dysregulation. Furthermore, we discuss the translational implications of targeting mitochondrial quality control and death pathways, proposing novel biomarkers and therapeutic strategies aimed at mitigating BPD progression. This review thus offers a unified mitochondrial-centric perspective, moving beyond descriptive mechanism to provide a conceptual framework for understanding BPD pathobiology and advancing targeted interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.